RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears

NCT01313351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 206

Last updated 2022-12-12

Study results available
· View outcomes & findings →

Summary

The RPS InflammaDry Detector™ is intended to detect elevated MMP-9 in human tears to aid in the diagnosis of patients with signs or symptoms of dry eye disease, in conjunction with other methods of clinical evaluation.

Conditions

  • Dry Eye

Interventions

DEVICE

RPS InflammaDry Detector™

A noninvasive immunoassay for detecting MMP-9 levels in tears

Sponsors & Collaborators

  • Rapid Pathogen Screening

    lead INDUSTRY

Principal Investigators

  • Robert Sambursky, MD · Rapid Pathogen Screening, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313351 on ClinicalTrials.gov